CareFusion Launches New AVAflex® Vertebral Balloon System for Targeted Balloon Placement
Also Introduces the pink Achieve® Breast Biopsy Device

SAN DIEGO, CA, March 24, 2014 – CareFusion (NYSE:CFN), a leading global medical technology company, launched its new AVAflex ® Vertebral Balloon System today at the 39th annual Scientific Meeting of the Society of Interventional Radiology (SIR).

The new system is the latest innovation in CareFusion’s AVAmax® Advanced Vertebral Augmentation portfolio. The focus of these products is to provide a minimally invasive solution to treat vertebral compression fractures, while also promoting safety for the patient, physician and staff. The AVAflex Vertebral Balloon System combines the unique features of the AVAflex Curved Vertebral Augmentation Needle and the AVAmax Vertebral Balloon to enable targeted balloon placement across the midline of the vertebral body, followed by targeted cement placement for optimal fill through a single pedicle.

“Our new AVAflex Vertebral Balloon System has a curved needle and balloon, featuring a flexible tip that is designed to target balloon placement and ultimately target cement placement,” said Michael Voss, senior vice president and general manager of Interventional Specialties for CareFusion. “The system also has the ability to create multiple cavities through a single insertion site, which can help minimize patient trauma.”

The new AVAflex Vertebral Balloon System is available in 15mm and 20mm balloon sizes, with a 30mm option to be launched in the coming months.

Additional CareFusion technologies and products debuting at SIR include:

  • The pink Achieve® biopsy device: A lightweight, one-handed design with delayed firing option for visualization of needle placement in lesion for precise breast biopsy samples. The new device features echogenic markings to support precise ultrasound positioning and is spring loaded for fast, accurate tissue penetration. The pink Achieve biopsy device also comes with an optional coaxial introducer for multiple sampling.
  • Safe-T PLUS lumbar puncture and myelogram tray: Features atraumatic BD Whitacre needles that are proven to reduce post-lumbar puncture headaches in lumbar puncture and myelogram patients1 through a pencil-point configuration that spreads dura fibers, helping minimize cerebrospinal fluid loss. The BD Whitacre needle provides precise access and control, and clear visualization of cerebrospinal fluid.

CareFusion will be exhibiting these new technologies at the SIR Scientific Meeting in booth 409.


About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit

For more information on BD, please visit

Troy Kirkpatrick

858 617 2361
Email Troy
1 Arendt, K., Demaerschalk, D., Wingerchuk, M. et al. “Atraumatic lumbar puncture needles: After all these years, are we still missing the point?” Neurologist, January 2009,15(1):17–20.